"Because of this rotation, this is what I want to do": Implementation and evaluation of a telehealth opioid use disorder clinical placement for nurse practitioner students.
Journal
Journal of the American Association of Nurse Practitioners
ISSN: 2327-6924
Titre abrégé: J Am Assoc Nurse Pract
Pays: United States
ID NLM: 101600770
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
19
05
2023
accepted:
25
08
2023
medline:
5
12
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
The lack of clinicians comfortable prescribing buprenorphine is a barrier to access for people with opioid use disorder (OUD). Accordingly, a telehealth OUD treatment clinic, Ophelia, launched a clinical training program for nurse practitioner (NP) students. The goal of this study was to assess a telehealth-based model of OUD clinical training. To evaluate the program, we (1) identified students' knowledge related to providing OUD care to patients before and after their clinical rotation with Ophelia and (2) characterized students' attitudes about providing OUD care following their clinical rotation with Ophelia. Online pre- and postsurveys were conducted with 57 and 29 students, respectively, and semistructured interviews were conducted with 19 students who completed clinical rotations with Ophelia. We used quantitative descriptive analysis to compare presurvey and postsurvey results and conducted thematic analysis to analyze qualitative interview data. We identified three themes from the interviews: the continuum of learning opportunities, the comfort providing OUD treatment following participants' clinical rotation, and the relevance of a substance use disorder clinical rotation for all NP students. The survey also supported these findings. Of note, there were descriptive differences between presurvey and postsurvey responses related to an increase in knowledge, preparedness, and acquisition of skills to treat OUD. Using a telehealth clinical rotation for NP students to learn about OUD treatment may represent an important step in increasing the number of clinicians who can prescribe buprenorphine. These findings can inform interventions and policies that target clinician training barriers.
Identifiants
pubmed: 37756445
doi: 10.1097/JXX.0000000000000949
pii: 01741002-990000000-00171
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Langues
eng
Pagination
826-834Informations de copyright
Copyright © 2023 American Association of Nurse Practitioners.
Références
Andrilla C. H. A., Moore T. E., Patterson D. G., Larson E. H. (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307
doi: 10.1111/jrh.12307
Aronowitz S. V., Engel-Rebitzer E., Dolan A., Oyekanmi K., Mandell D., Meisel Z., South E., Lowenstein M. (2021). Telehealth for opioid use disorder treatment in low-barrier clinic settings: An exploration of clinician and staff perspectives. Harm Reduction Journal, 18(1), 119. https://doi.org/10.1186/s12954-021-00572-7
doi: 10.1186/s12954-021-00572-7
Barnett M. L., Lee D., Frank R. G. (2019). In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants. Health Affairs, 38(12), 2048–2056. https://doi.org/10.1377/hlthaff.2019.00859
doi: 10.1377/hlthaff.2019.00859
Jones C. M., McCance-Katz E. F. (2019). Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction, 114(3), 471–482. https://doi.org/10.1111/add.1443
doi: 10.1111/add.1443
Larney S., Hall W. (2019). A major expansion of opioid agonist treatment is needed to reduce overdose deaths in the USA. The Lancet Public Health, 4(2), e77–e78. https://doi.org/10.1016/S2468-2667(19)30001-5
doi: 10.1016/S2468-2667(19)30001-5
Livingston J. D. (2021). A framework for assessing structural stigma in health-care contexts for people with mental health and substance use issues. Mental Health Commission of Canada.
Mattson C. L., Tanz L. J., Quinn K., Kariisa M., Patel P., Davis N. L. (2021). Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR. Morbidity and Mortality Weekly Report, 70(6), 202–207. https://doi.org/10.15585/mmwr.mm7006a4
doi: 10.15585/mmwr.mm7006a4
McBain R. K., Dick A., Sorbero M., Stein B. D. (2020). Growth and distribution of buprenorphine-waivered providers in the United States, 2007–2017. Annals of Internal Medicine, 172(7), 504–506. https://doi.org/10.7326/M19-2403
doi: 10.7326/M19-2403
Olsen Y., Fitzgerald R. M., Wakeman S. E. (2021). Overcoming barriers to treatment of opioid use disorder. JAMA, 325(12), 1149–1150. https://doi.org/10.1001/jama.2021.1741
doi: 10.1001/jama.2021.1741
Phillips J. M., Phillips C. R., Kauffman K. R., Gainey M., Schnur P. L. (2019). Academic–practice partnerships: A win-win. The Journal of Continuing Education in Nursing, 50(6), 282–288.
Saloner B., Andraka Christou B., Gordon A. J., Stein B. D. (2021). Article commentary: It will end in tiers: A strategy to include “Dabblers” in the buprenorphine workforce after the X-waiver. Substance Abuse, 42(2), 153–157. https://doi.org/10.1080/08897077.2021.1903659
doi: 10.1080/08897077.2021.1903659
Spetz J., Hailer L., Gay C., Tierney M., Schmidt L., Phoenix B., Chapman S. (2022). Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements. JAMA Network Open, 5(5), e225996. https://doi.org/10.1001/jamanetworkopen.2022.5996
doi: 10.1001/jamanetworkopen.2022.5996
Substance Abuse. (2020). Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health.
Velander J. R. (2018). Suboxone: Rationale, science, misconceptions. The Ochsner Journal, 18(1), 23–29.
Volkow N. D. (2018). Medications for opioid use disorder: Bridging the gap in care. The Lancet, 391(10118), 285–287. https://doi.org/10.1016/S0140-6736(17)32893-3
doi: 10.1016/S0140-6736(17)32893-3
Wood E., Elliott M. (2020). Opioid addiction stigma: The intersection of race, social class, and gender. Substance Use & Misuse, 55(5), 818–827. https://doi.org/10.1080/10826084.2019.1703750
doi: 10.1080/10826084.2019.1703750